immunoglobulin therapy in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Gharebaghi, 2020 0.00 [0.00; 0.09]
Raman, 2021 0.49 [0.02; 15.10]
Sakoulas, 2020 0.29 [0.03; 3.13]
Tabarsi, 2020 1.10 [0.45; 2.67]
0.20 [0.02 ; 1.98 ] Gharebaghi, 2020, Raman, 2021, Sakoulas, 2020, Tabarsi, 2020 4 74% 277 moderate not evaluable deathsdetailed results Gharebaghi, 2020 0.00 [0.00; 0.09]
Raman, 2021 0.49 [0.02; 15.10]
Sakoulas, 2020 0.29 [0.03; 3.13]
Tabarsi, 2020 1.10 [0.45; 2.67]
0.20 [0.02 ; 1.98 ] Gharebaghi, 2020, Raman, 2021, Sakoulas, 2020, Tabarsi, 2020 4 74% 277 moderate not evaluable mechanical ventilationdetailed results Sakoulas, 2020 0.19 [0.03; 1.11]
Tabarsi, 2020 1.49 [0.59; 3.78]
0.61 [0.08 ; 4.52 ] Sakoulas, 2020, Tabarsi, 2020 2 76% 118 moderate not evaluable radiologic improvement (14-day)detailed results Tabarsi, 2020 2.33 [0.45; 12.00]
2.33 [0.45 ; 12.00 ] Tabarsi, 2020 1 0% 84 NA not evaluable viral clearance detailed results Out of scale Raman, 2021 36.42 [10.85; 122.18]
36.42 [10.85 ; 122.18 ] Raman, 2021 1 0% 100 NA not evaluable viral clearance by day 14detailed results Out of scale Raman, 2021 36.42 [10.85; 122.18]
36.42 [10.85 ; 122.18 ] Raman, 2021 1 0% 100 NA not evaluable ICU admissiondetailed results Tabarsi, 2020 0.56 [0.18; 1.74]
0.56 [0.18 ; 1.74 ] Tabarsi, 2020 1 0% 84 NA not evaluable serious adverse eventsdetailed results Raman, 2021 0.49 [0.02; 15.10]
0.49 [0.02 ; 15.10 ] Raman, 2021 1 0% 100 NA not evaluable adverse eventsdetailed results Raman, 2021 1.36 [0.56; 3.30]
Sakoulas, 2020 1.00 [0.02; 53.46]
1.34 [0.56 ; 3.18 ] Raman, 2021, Sakoulas, 2020 2 0% 134 moderate not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-02 22:54 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 521
- roots T: 290